CPH
Physician Daily · Monday, August 24, 2026
Newsletters Sign in ON AIR
CrosspointHealthNEWS + REFERENCE LIBRARY
Diagnosis Sheet Schizophrenia Spectrum and Other Psychotic Disorders DSM-5-TR 297.1 | ICD-10-CM F22

Delusional Disorder

One or more fixed delusions lasting 1 month or longer, with functioning outside the delusion largely preserved and no other prominent psychosis.

Lifetime prevalence~0.02-0.2%
Typical onsetMiddle to late adulthood
Sex ratioNear equal; jealous type male
CourseChronic; often lifelong

Clinical picture

  • A single encapsulated delusional system dominates, whether persecutory, jealous, erotomanic, somatic, or grandiose, while the rest of the personality stays intact.
  • Behavior outside the delusion appears unremarkable, so patients hold jobs and relationships and almost never present voluntarily to mental health services.
  • First presentation is usually through dermatology, infectious disease, plastic surgery, law enforcement, or the courts rather than through psychiatry.
  • Hallucinations, when present, are limited and thematically tied to the delusion, such as tactile formication in delusional infestation cases.
  • Affect is congruent with the delusional content, producing irritability, litigiousness, or stalking behavior rather than global disorganization.
  • Insight is absent by definition, and challenging the belief directly ruptures the alliance and predicts immediate dropout from treatment.

Criteria snapshot

  • One or more delusions persist for at least 1 month, which is the minimum duration threshold and the defining requirement of the diagnosis.
  • The full symptom picture for schizophrenia has never been met; hallucinations are absent or minor and are related to the delusional theme.
  • Apart from the delusion and its direct consequences, functioning is not markedly impaired and behavior is not obviously bizarre or odd to others.
  • Any concurrent mood episodes are brief relative to the duration of the delusional periods, separating this from psychotic mood disorders.
  • Specify subtype as erotomanic, grandiose, jealous, persecutory, somatic, or mixed, note bizarre content, and exclude substances and medical causes.

Neurobiology

  • Striatal dopamine dysregulation is implicated but appears milder and more focal than in schizophrenia, consistent with the partial antipsychotic response seen.
  • Right hemisphere and frontotemporal dysfunction is reported, particularly in delusional misidentification syndromes and in late-onset presentations.
  • Sensory impairment, especially untreated hearing and vision loss, together with social isolation, is an established risk factor in older adults.
  • Family studies show elevated rates of delusional disorder and of paranoid and avoidant personality traits, with weaker schizophrenia loading than expected.
  • Structural imaging is usually unremarkable, so new-onset delusions after age 50 warrant neuroimaging for tumor, stroke, or neurodegenerative disease.
  • Dopaminergic agents, stimulants, corticosteroids, and levodopa can precipitate an identical presentation and must be reviewed in every single case.

Psychology

  • Jumping-to-conclusions bias, meaning decisions made on minimal evidence, is more pronounced than in schizophrenia and sustains conviction against disconfirmation.
  • An externalizing and personalizing attributional style assigns negative events to the hostile intentions of others, protecting fragile self-esteem.
  • Theory-of-mind errors combined with hypervigilance to threat cues generate paranoid interpretations of ordinary and ambiguous social behavior.
  • Confirmation bias and selective attention convert coincidences into corroborating evidence, so the belief system grows more elaborate over time.
  • Premorbid paranoid, schizoid, or narcissistic traits, plus immigration, deafness, and social marginalization, all increase vulnerability to onset.

Differential & comorbidity

  • Schizophrenia is excluded by the absence of prominent hallucinations, disorganization, and negative symptoms and by the preservation of daily functioning.
  • Body dysmorphic disorder and obsessive-compulsive disorder with absent insight are separated by phenomenology and insight specifiers, not by conviction alone.
  • Rule out substance-induced psychosis, dementia, delirium, temporal lobe epilepsy, and paraneoplastic or autoimmune syndromes in any late-onset case.
  • Depression is the most common comorbidity, often secondary to the social consequences of the delusion, followed by anxiety and profound isolation.
  • Assess risk explicitly: jealous and persecutory subtypes carry elevated risk of stalking, assault, and homicide directed at specific named individuals.

Pharmacologic treatment

  • Antipsychotic response is partial and slower than in schizophrenia; risperidone 2-6 mg/day or olanzapine 5-15 mg/day are reasonable first choices.
  • Pimozide 2-8 mg/day carries the strongest tradition in delusional infestation but requires baseline and follow-up ECG for QTc prolongation.
  • Allow 8-12 weeks at an adequate dose before declaring failure, and expect reduced preoccupation and distress rather than outright retraction of the belief.
  • Treat comorbid depression with an SSRI; SSRIs or clomipramine may help somatic-type presentations that overlap with the obsessive-compulsive spectrum.
  • Adherence is the central obstacle, so frame medication as targeting stress, sleep, and preoccupation rather than as treatment for a psychotic illness.

Psychotherapy

  • CBT for psychosis works through collaborative empiricism, testing the predictions the belief generates rather than disputing it, across 16-24 sessions.
  • Prioritize engagement and alliance for several sessions before any belief-focused work, because premature challenge strongly predicts dropout.
  • Motivational interviewing techniques address ambivalence about medication and avoid the confrontation over insight that derails treatment.
  • Behavioral experiments and reality-testing homework yield modest reductions in conviction and considerably larger reductions in associated distress.
  • Family involvement supplies collateral history, monitors risk to third parties, and prevents accommodation of delusion-driven behavior at home.

Adjunct options

  • Correct sensory deficits directly, since hearing aids and cataract surgery measurably reduce paranoid ideation in late-onset presentations.
  • Coordinate with dermatology or the referring specialist in delusional infestation, because joint or shared visits substantially improve retention.
  • Document and manage risk toward named targets, including duty-to-warn analysis, protective orders, and an explicit written safety plan.
  • Track conviction over time with the PANSS delusion items or the Brown Assessment of Beliefs Scale rather than relying on impression.
  • Long-acting injectable antipsychotics are an option when repeated nonadherence drives relapse, escalating behavior, and risk to others.

Clinical pearls

  • Never argue the delusion; treat the distress and preoccupation it generates.
  • New delusions after age 50 mean imaging and a medication review before a psychiatric label.
  • Jealous and persecutory subtypes require an explicit violence risk assessment.

References

  • American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
  • Boland, R., Verduin, M. L., & Ruiz, P. (2021). Kaplan & Sadock's synopsis of psychiatry (12th ed.). Wolters Kluwer.
  • Freeman, D., & Garety, P. (2014). Advances in understanding and treating persecutory delusions: A review. Social Psychiatry and Psychiatric Epidemiology, 49(8), 1179-1189. https://doi.org/10.1007/s00127-014-0928-7
  • National Institute for Health and Care Excellence. (2014). Psychosis and schizophrenia in adults: Prevention and management (NICE Guideline No. CG178). https://www.nice.org.uk/guidance/cg178
  • National Institute of Mental Health. (n.d.). Schizophrenia. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/topics/schizophrenia
  • Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.